Ardent Health Reports Q4 2025 Profit Decline, Issues Lower 2026 Guidance Amid Headwinds
ARDT is trading near its 52-week low of $8.07 (5.9% above the low).
Summary
Ardent Health reported a sharp decline in Q4 2025 profits and issued 2026 guidance that projects lower Adjusted EBITDA and diluted EPS compared to 2025 actuals, citing various industry headwinds.
Key Events · Earnings and Guidance · ARDT
-
Q4 2025 Profitability Decline
Net income attributable to Ardent Health, Inc. decreased to $45 million in Q4 2025 from $114 million in Q4 2024. Adjusted EBITDA fell 26.6% year-over-year to $134 million.
-
Lower 2026 Financial Guidance
The company issued full-year 2026 Adjusted EBITDA guidance of $485 million to $535 million, which is below the $545 million achieved in full-year 2025. Diluted EPS guidance for 2026 is $0.90 to $1.27, also indicating a potential decline from 2025's $0.96.
-
Operational Headwinds Cited
Management attributed the cautious 2026 outlook to annualization of elevated professional fees, payor denials, Exchange disruption, and restoration of short-term compensation.
-
Modest Share Repurchase
During Q4 2025, the company repurchased 0.35 million shares for $3 million, with $47 million remaining under its authorization. This is a minor positive against the broader financial results.
Analysis · ARDT · Industrial Applications And Services
Ardent Health, Inc. reported a significant year-over-year decline in profitability for Q4 2025, with net income attributable to the company falling to $45 million from $114 million and Adjusted EBITDA decreasing by 26.6% to $134 million. While full-year 2025 revenue and Adjusted EBITDA showed growth, the company's initial full-year 2026 guidance projects a notable decrease in profitability, with Adjusted EBITDA expected to be between $485 million and $535 million, down from $545 million in 2025. Diluted EPS guidance for 2026 also indicates a potential decline. Management cited headwinds including elevated professional fees, payor denials, Exchange disruption, and restoration of short-term compensation. This negative outlook, following recent class action lawsuits, suggests ongoing operational challenges that could impact investor sentiment.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARDT was trading at $8.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $8.07 to $15.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.